The dipeptide Phe-Phe amide attenuates signs of hyperalgesia, allodynia and nociception in diabetic mice using a mechanism involving the sigma receptor system

Molecular Pain

Junzo Kamei¹  Fred Nyberg²  Mathias Hallberg²  Anja Sandström³  Rebecca Fransson³  Yuki Nakanishi¹  Takayuki Koizumi¹  Megumi Asato¹  Anna Carlsson²  Masahiro Ohsawa¹ 

[1] Department of Pathophysiology & Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 4-41, Ebara 2-chome, Shinagawa-ku, Tokyo 142-8501, Japan;Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, S-751 24 Uppsala, Sweden;Department of Medicinal Chemistry, Uppsala University, P.O. Box 574, SE-751 23 Uppsala, Sweden

关键词: Substance P_1-7;    σ₁ receptor;    Phe-Phe amide;    Opioid receptors;    Hyperalgesia;    Diabetes;    Antinociception;    Allodynia;   

Others  :  865659
DOI  :  10.1186/1744-8069-7-85

 received in 2011-08-21, accepted in 2011-10-31,  发布年份 2011

【 摘 要 】

Background

Previous studies have demonstrated that intrathecal administration of the substance P amino-terminal metabolite substance P_1-7 (SP_1-7) and its C-terminal amidated congener induced antihyperalgesic effects in diabetic mice. In this study, we studied a small synthetic dipeptide related to SP_1-7 and endomorphin-2, i.e. Phe-Phe amide, using the tail-flick test and von Frey filament test in diabetic and non-diabetic mice.

Results

Intrathecal treatment with the dipeptide increased the tail-flick latency in both diabetic and non-diabetic mice. This effect of Phe-Phe amide was significantly greater in diabetic mice than non-diabetic mice. The Phe-Phe amide-induced antinociceptive effect in both diabetic and non-diabetic mice was reversed by the σ₁ receptor agonist (+)-pentazocine. Moreover, Phe-Phe amide attenuated mechanical allodynia in diabetic mice, which was reversible by (+)-pentazocine. The expression of spinal σ1 receptor mRNA and protein did not differ between diabetic mice and non-diabetic mice. On the other hand, the expression of phosphorylated extracellular signal-regulated protein kinase 1 (ERK1) and ERK2 proteins was enhanced in diabetic mice. (+)-Pentazocine caused phosphorylation of ERK1 and ERK2 proteins in non-diabetic mice, but not in diabetic mice.

Conclusions

These results suggest that the spinal σ₁ receptor system might contribute to diabetic mechanical allodynia and thermal hyperalgesia, which could be potently attenuated by Phe-Phe amide.

【 授权许可】

   
2011 Ohsawa et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
• [2]Feldman EL, Russell JW, Sullivan KA, Golovoy D: New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 1999, 12:553-563.
• [3]Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA: Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 2000, 23:510-517.
• [4]Kingery WS: A critical review of controlled clinical trrials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1990, 73:123-139.
• [5]Carlsson A, Ohsawa M, Hallberg M, Nyberg F, Kamei J: Substance P(1-7) induces antihyperalgesia in diabetic mice through a mechanism involving the naloxone-sensitive sigma receptors. Eur J Pharmacol 2010, 626:250-255.
• [6]von Euler US, Gaddum JH: An unidentified depressor substance in certain tissue extracts. J Physiol 1931, 72:74-87.
• [7]Hökfelt T, Pernow B, Wahren J: Substance P: a pioneer amongst neuropeptides. J Int Med 2001, 249:27-40.
• [8]Hall ME, Stewart JM: Substance P and Behavior: Opposite effects of N-terminal and C-terminal fragments. Peptides 1983, 4:763-768.
• [9]Hallberg M, Nyberg F: Neuropeptide conversion to bioactive fragments - an important Pathway in neuromodulation. Curr Prot Pept Sci 2003, 4:31-44.
• [10]Sakurada T, Le Grevès P, Stewart J, Terenius L: Measurement of Substance P metabolites in rat CNS. J Neurochem 1985, 44:718-722.
• [11]Stewart JM, Hall ME, Harkins J, Frederickson RCA, Terenius L, Hökfelt T, Krivoy WA: A fragment of substance P with specific activity: SP(1-7). Peptides 1982, 3:851-857.
• [12]Wiktelius D, Khalil Z, Nyberg F: Modulation of peripheral inflammation by the substance P N-terminal metabolite substance P1-7. Peptides 2006, 27:1490-1497.
• [13]Kreeger JS, Larson AA: The Substance P amino-terminal metabolite Substance P(1-7), administered peripherally, prevents the development of acute morphine tolerance and attenuates the expression of withdrawal in mice. J Pharmacol Exp Ther 1996, 279:662-667.
• [14]Zhou Q, Nyberg F: Injection of substance P (SP) N-terminal fragment SP(1-7) into the ventral tegmental area modulates the levels of nucleus accumbens dopamine and dihydroxyphenylacetic acid in male rats during morphine withdrawal. Neurosci Lett 2002, 320:117-120.
• [15]Botros M, Hallberg M, Johansson T, Zhou Q, Lindeberg G, Frändberg PA, Tömböly C, Tóth G, Le Grevès P, Nyberg F: Endomorphin-1 and endomorphin-2 differentially interact with specific binding sites for substance P (SP) aminoterminal SP1-7 in the rat spinal cord. Peptides 2006, 27:753-759.
• [16]Igwe OJ, Kim DC, Seybold VS, Larson AA: Specific binding of substance P aminoterminal heptapeptide [SP(1-7)] to mouse brain and spinal cord membranes. J Neurosci 1990, 10:3653-3663.
• [17]Botros M, Johansson T, Zhou Q, Lindeberg G, Tömböly C, Tóth G, Le Grevès P, Nyberg F, Hallberg M: Endomorphins interact with the substance P (SP) aminoterminal SP1-7 binding in the ventral tegmental area of the rat brain. Peptides 2008, 29:1820-1824.
• [18]Ohsawa M, Carlsson A, Asato M, Koizumi T, Nakanishi Y, Fransson R, Sandström A, Hallberg M, Nyberg F, Kamei J: The effect of substance P1-7 amide on nociceptive threshold in diabetic mice. Peptides 2011, 32:93-98.
• [19]Zhou Q, Carlsson A, Botros M, Fransson R, Sandström A, Gordh T, Hallberg M, Nyberg F: The C-terminal amidated analogue of the substance P (SP) fragment SP(1-7) attenuates the expression of naloxone-precipitated withdrawal in morphine dependent rats. Peptides 2009, 30:2418-2422.
• [20]Hornfeldt CS, Kitto KF, Larson AA: Evidence that the NH2-terminus of substance P modulates N-methyl-D-aspartate-induced activity by an action involving σ receptors. Eur J Pharmacol 1996, 306:15-22.
• [21]Larson AA, Sun X: Modulation of kainic acid-induced activity in the mouse spinal cord by the amino terminus of substance P: sensitivity to opioid antagonists. J Pharmacol Exp Ther 1993, 265:159-165.
• [22]de la Puente B, Nadal X, Portillo-Salido E, Sánchez-Arroyos R, Ovalle S, Palacios G, Muro A, Romero L, Entrena JM, Baeyens JM, López-García JA, Maldonado R, Zamanillo D, Vela JM: Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain 2009, 145:294-303.
• [23]Fransson R, Botros M, Nyberg F, Lindeberg G, Sandström A, Hallberg M: Small peptides mimicking substance P (1-7) and encompassing a C-terminal amide functionality. Neuropeptides 2008, 42:31-37.
• [24]Fransson R, Botros M, Sköld C, Nyberg F, Lindeberg G, Hallberg M, Sandström A: Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem 2010, 53:2383-2389.
• [25]Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE: The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009, 323:934-937.
• [26]Tsao LI, Su TP: Naloxone-sensitive, haloperidol-sensitive, [3H](+)SKF-10047-binding protein partially purified from rat liver and rat brain membranes: an opioid/sigma receptor? Synapse 1997, 25:117-124.
• [27]Kim HW, Roh DH, Yoon SY, Seo HS, Kwon YB, Han HJ, Kim KW, Beitz AJ, Lee JH: Activation of the spinal sigma-1 receptor enhances NMDA-induced pain via PKC- and PKA-dependent phosphorylation of the NR1 subunit in mice. Br J Pharmacol 2008, 154:1125-1134.
• [28]Baron R: Mechanisms of disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006, 2:95-106.
• [29]Meller ST, Dykstra CL, Gebhart GF: Investigations of the possible role for carbon monoxide (CO) in thermal and mechanical hyperalgesia in the rat. Neuroreport 1994, 5:2337-2341.
• [30]Nieto FR, Entrena JM, Cendán CM, Pozo ED, Vela JM, Baeyens JM: Tetrodotoxin inhibits the development and expression of neuropathic pain induced by paclitaxel in mice. Pain 2008, 137:520-531.
• [31]Treede RD, Meyer RA, Raja SN, Campbell JN: Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992, 38:397-421.
• [32]Ola MS, Moore P, Maddox D, El-Sherbeny A, Huang W, Roon P, Agarwal N, Ganapathy V, Smith SB: Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res 2002, 107:97-107.
• [33]Mardon K, Kassiou M, Donald A: Effects of streptozotocin-induced diabetes on neuronal sigma receptors in the rat brain. Life Sci 1999, 65:PL281-PL286.
• [34]Bergeron R, de Montigny C, Debonnel G: Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci 1996, 16:1193-1202.
• [35]Hayashi T, Kagaya A, Takebayashi M, Shimizu M, Uchitomi Y, Motohashi N, Yamawaki S: Modulation by sigma ligands of intracellular free Ca++ mobilization by N-methyl-D-aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 1995, 275:207-214.
• [36]Martina M, Turcotte ME, Halman S, Bergeron R: The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol 2007, 578:143-157.
• [37]Monnet FP, Debonnel G, Junien JL, De Montigny C: N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur J Pharmacol 1990, 179:441-445.
• [38]Monnet FP, Morin-Surun MP, Leger J, Combettes L: Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther 2003, 307:705-712.
• [39]Monnet FP: Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell 2005, 97:873-883.
• [40]Su TP, Hayashi T: Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem 2003, 10:2073-2080.
• [41]Kawasaki Y, Kohno T, Zhuang ZY, Brenner GJ, Wang H, Van Der Meer C, Befort K, Woolf CJ, Ji RR: Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. J Neurosci 2004, 24:8310-8321.
• [42]Zhuang ZY, Gerner P, Woolf CJ, Ji RR: ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005, 114:149-159.
• [43]D'amour FE, Smith DL: A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941, 72:74-79.
• [44]Ohsawa M, Kamei J: Possible involvement of spinal protein kinase C in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 1999, 372:221-228.
• [45]Hylden JL, Wilcox GL: Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67:313-316.
• [46]Kamei J, Iwamoto Y, Misawa M, Nagase H, Kasuya Y: Antinociceptive effect of L-arginine in diabetic mice. Eur J Pharmacol 1994, 254:113-117.
• [47]Wu HE, Hong JS, Tseng LF: Stereoselective action of (+)-morphine over (-)-morphine in attenuating the (-)-morphine-produced antinociception via the naloxone-sensitive sigma receptor in the mouse. Eur J Pharmacol 2007, 571:145-151.